Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walid Shalata

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Biomedicines|March 28, 2026
Evaluating the Therapeutic Impact of Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung CancerKeren Rouvinov, Rashad Naamneh, Alexander Yakobson, et al.
Cancers|May 25, 2024
Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB StatusWalid Shalata, Natalie Maimon Rabinovich, Abed Agbarya, et al.
Life (Basel, Switzerland)|May 4, 2026
Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving ImmunotherapyAlexander Yakobson, Fahed Abu Salamah, Ibrahim Alatawneh, et al.
Journal of Clinical Medicine|November 9, 2024
Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung CancerWalid Shalata, Sameh Daher, Natali Maimon Rabinovitch, et al.
Diagnostics (Basel, Switzerland)|February 27, 2026
The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern OncologyKeren Rouvinov, Rashad Naamneh, Alexander Yakobson, et al.
Frontiers in Oncology|October 7, 2022
Real-world efficacy and safety of mobocertinib in <i>EGFR</i> exon 20 insertion-mutated lung cancerWaleed Kian, Petros Christopoulos, Areen A Remilah, et al.
Medical Sciences (Basel, Switzerland)|September 22, 2025
Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain MetastasesWalid Shalata, Rashad Naamneh, Wenad Najjar, et al.
Case Reports in Oncology|March 29, 2021
Epithelioid Hemangioendothelioma and Epithelioid Hemangioma: Pazopanib as a Potential Salvage TherapyAlexander Yakobson, Wafeek Alguayn, Walid Shalata, et al.
Medical Sciences (Basel, Switzerland)|April 24, 2026
Survival Outcomes in Lymph Node-Positive Merkel Cell Carcinoma (Stage III): A Comparison Between Known and Unknown Primary Tumors and Their Sun Exposure SitesRonen Brenner, Hanna T Frumin Edri, Sabri El-Saied, et al.
JTO Clinical and Research Reports|April 22, 2026
Clinical and Genomic Characteristics of Patients With Advanced NSCLC Who Have Long-Term Response to First-Line Immunotherapy: A Real-World StudySameh Daher, Walid Shalata, Natali Shirron, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Biomedicines|March 28, 2026
Evaluating the Therapeutic Impact of Immune Checkpoint Inhibitors in the Management of Brain Metastases from Non-Small Cell Lung CancerKeren Rouvinov, Rashad Naamneh, Alexander Yakobson, et al.
Cancers|May 25, 2024
Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB StatusWalid Shalata, Natalie Maimon Rabinovich, Abed Agbarya, et al.
Life (Basel, Switzerland)|May 4, 2026
Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving ImmunotherapyAlexander Yakobson, Fahed Abu Salamah, Ibrahim Alatawneh, et al.
Journal of Clinical Medicine|November 9, 2024
Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung CancerWalid Shalata, Sameh Daher, Natali Maimon Rabinovitch, et al.
Diagnostics (Basel, Switzerland)|February 27, 2026
The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern OncologyKeren Rouvinov, Rashad Naamneh, Alexander Yakobson, et al.
Frontiers in Oncology|October 7, 2022
Real-world efficacy and safety of mobocertinib in <i>EGFR</i> exon 20 insertion-mutated lung cancerWaleed Kian, Petros Christopoulos, Areen A Remilah, et al.
Medical Sciences (Basel, Switzerland)|September 22, 2025
Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain MetastasesWalid Shalata, Rashad Naamneh, Wenad Najjar, et al.
Case Reports in Oncology|March 29, 2021
Epithelioid Hemangioendothelioma and Epithelioid Hemangioma: Pazopanib as a Potential Salvage TherapyAlexander Yakobson, Wafeek Alguayn, Walid Shalata, et al.
Medical Sciences (Basel, Switzerland)|April 24, 2026
Survival Outcomes in Lymph Node-Positive Merkel Cell Carcinoma (Stage III): A Comparison Between Known and Unknown Primary Tumors and Their Sun Exposure SitesRonen Brenner, Hanna T Frumin Edri, Sabri El-Saied, et al.
JTO Clinical and Research Reports|April 22, 2026
Clinical and Genomic Characteristics of Patients With Advanced NSCLC Who Have Long-Term Response to First-Line Immunotherapy: A Real-World StudySameh Daher, Walid Shalata, Natali Shirron, et al.
Pageof 8